Tag: remdesivir

Ridgeback partnered with the pharmaceutical giant Merck to accelerate its development.The Emory researchers named their drug molnupiravir, after Mjölnir—the hammer of Thor. It turns out that this was not hyperbole. Last month, Merck and Ridgeback announced that molnupiravir could reduce by half the chances that a person infected by the coronavirus would need to be hospitalized. The drug was so overwhelmingly effective that an independent committee asked the researchers to stop their Phase III trial early—it would have been unethical to continue giving participants placebos.

None of the nearly four hundred patients who received molnupiravir in the trial went on to die, and the drug had no major side effects. On November 4th, the U.K. became the first country to approve molnupiravir; many observers expect that an emergency-use authorization will come from the U.S. Food and Drug Administration in December.

Oral antivirals like molnupiravir could transform the treatment of COVID-19, and of the pandemic more generally. Currently, treatments aimed at fighting COVID—mainly monoclonal antibodies and antiviral drugs like remdesivir—are given through infusion or injection, usually in clinics or hospitals. By the time people manage to arrange a visit, they are often too sick to receive much benefit. Molnupiravir, however, is a little orange pill.

A person might wake up, feel unwell, get a rapid COVID test, and head to the pharmacy around the corner to pick up a pack. A full course, which needs to start within five days of the appearance of symptoms, consists of forty pills—four capsules taken twice a day, for five days. Merck is now testing whether molnupiravir can prevent not just hospitalization after infection but also infection after exposure.

If that’s the case, then the drug might be taken prophylactically—you could get a prescription when someone in your household tests positive, even if you haven’t.Molnupiravir is—and is likely to remain—effective against all the major coronavirus variants. In fact, at least in the lab, it works against any number of RNA viruses besides SARS-CoV-2, including Ebola, hepatitis C, R.S.V., and norovirus. Instead of targeting the coronavirus’s spike protein, as vaccine-generated antibodies do, molnupiravir attacks the virus’s basic replication machinery. The spike protein mutates over time, but the replication machinery is mostly set in stone, and compromising that would make it hard for the virus to evolve resistance.

Once it’s inside the body, molnupiravir breaks down into a molecule called NHC. As my colleague Matthew Hutson explained, in a piece about antiviral drugs published last year, NHC is similar to cytosine, one of the four “bases” from which viral RNA is constructed; when the coronavirus’s RNA begins to copy itself, it slips into cytosine’s spot, in a kind of “Freaky Friday” swap. The molecule evades the virus’s genetic proofreading mechanisms and wreaks havoc, pairing with other bases, introducing a bevy of errors, and ultimately crashing the system.

A drug that’s so good at messing with viral RNA has led some to ask whether it messes with human DNA, too. (Merck’s trial excluded pregnant and breast-feeding women, and women of childbearing age had to be on contraceptives.) This is a long-standing concern about antiviral drugs that introduce genomic errors. A recent study suggests that molnupiravir, taken at high doses and for extended periods, can, in fact, introduce mutations into DNA. But, as the biochemist Derek Lowe noted, in a blog post for Science, these findings probably don’t apply directly to the real-world use of molnupiravir in COVID patients. The study was conducted in cells, not live animals or humans.

The cells were exposed to the drug for more than a month; even at the highest doses, it caused fewer mutations than were created by a brief exposure to ultraviolet light. Meanwhile, Merck has run a battery of tests—both in the lab and in animal models—and found no evidence that molnupiravir causes problematic mutations at the dose and duration at which it will be prescribed.With winter approaching, America is entering another precarious moment in the pandemic. Coronavirus cases have spiked in many European countries—including some with higher vaccination rates than the U.S.—and some American hospitals are already starting to buckle under the weight of a new wave. Nearly fifty thousand Americans are currently hospitalized with COVID-19.

It seems like molnupiravir is arriving just when we need it.It isn’t the only antiviral COVID pill, either. A day after the U.K. authorized Merck’s drug, Pfizer announced that its antiviral, Paxlovid, was also staggeringly effective at preventing the progression of COVID-19 in high-risk patients. The drug, when taken within three days of the onset of symptoms, reduced the risk of hospitalization by nearly ninety per cent. Only three of the nearly four hundred people who took Paxlovid were hospitalized, and no one died; in the placebo group, there were twenty-seven hospitalizations and seven deaths. Paxlovid is administered along with another antiviral medication called ritonavir, which slows the rate at which the former drug is broken down by the body.

Like Merck, Pfizer is now examining whether Paxlovid can also be used to prevent infections after an exposure. Results are expected early in 2022. (It’s not yet known how much of a difference the drugs will make for vaccinated individuals suffering from breakthrough infections; Merck’s and Pfizer’s trials included only unvaccinated people with risk factors for severe disease, such as obesity, diabetes, or older age. Vaccinated individuals are already much less likely to be hospitalized or die of COVID-19.)

Living in an Age of ExtinctionPaxlovid interrupts the virus’s replication not by messing with its genetic code but by disrupting the way its proteins are constructed. When a virus gets into our cells, its RNA is translated into proteins, which do the virus’s dirty work. But the proteins are first built as long strings called polypeptides; an enzyme called protease then slices them into the fragments from which proteins are assembled.

If you can’t cut the plywood, you can’t build the table, and Paxlovid blunts the blade. Because they employ separate mechanisms to defeat the virus, Paxlovid and molnupiravir could, in theory, be taken together. Some viruses that lead to chronic infections, including H.I.V. and hepatitis C, are treated with drug cocktails to prevent them from evolving resistance against a single line of attack. This approach is less common with respiratory viruses, which don’t generally persist in the body for long periods.

But combination antiviral therapy against the coronavirus could be a subject of study in the coming months, especially among immunocompromised patients, in whom the virus often lingers, allowing it the time and opportunity to generate mutations.

Merck will be producing a lot of molnupiravir. John McGrath, the company’s senior vice-president of manufacturing, told me that Merck began bolstering its manufacturing capacity long before the Phase III trial confirmed how well the drug worked. Normally, a company assesses demand for a product, then brings plants online slowly. For molnupiravir, Merck has already set up seventeen plants in eight countries across three continents. It now has the capacity to produce ten million courses of treatment by the end of this year, and at least another twenty million next year.

It expects molnupiravir to generate five to seven billion dollars in revenue by the end of 2022.How much will all these pills soften the looming winter surge? As has been true throughout the pandemic, the answer depends on many factors beyond their effectiveness. The F.D.A. could authorize molnupiravir within weeks, and Paxlovid soon afterward. But medications only work if they make their way into the body. Timing is critical. The drugs should be taken immediately after symptoms start—ideally, within three to five days. Whether people can benefit from them depends partly on the public-health infrastructure where they live. In Europe, rapid at-home COVID tests are widely available.

Twenty months into the pandemic, this is not the case in much of the U.S., and many Americans also lack ready access to affordable testing labs that can process PCR results quickly.Consider one likely scenario. On Monday, a man feels tired but thinks little of it. On Tuesday, he wakes up with a headache and, in the afternoon, develops a fever. He schedules a COVID test for the following morning. Two days later, he receives an e-mail informing him that he has tested positive. By now, it’s Friday afternoon. He calls his doctor’s office; someone picks up and asks the on-call physician to write a prescription. The man rushes to the pharmacy to get the drug within the five-day symptom-to-pill window.

Envision how the week might have unfolded for someone who’s uninsured, elderly, isolated, homeless, or food insecure, or who doesn’t speak English. Taking full advantage of the new drugs will require vigilance, energy, and access.Antivirals could be especially valuable in places like Africa, where only six per cent of the population is fully vaccinated. As they did with the vaccines, wealthy countries, including the U.S. and the U.K., have already locked in huge contracts for the pills; still, Merck has taken steps to expand access to the developing world.

It recently granted royalty-free licenses to the Medicines Patent Pool, a U.N.-backed nonprofit, which will allow manufacturers to produce generic versions of the drug for more than a hundred low- and middle-income countries. (Pfizer has reached a similar agreement with the Patent Pool; the company also announced that it will forgo royalties for Paxlovid in low-income countries, both during and after the pandemic.) As a result, a full course of molnupiravir could cost as little as twenty dollars in developing countries, compared with around seven hundred in the U.S. “Our goal was to bring this product to high-, middle-, and low-income countries at fundamentally the same time,” Paul Schaper, Merck’s executive director of global pharmaceutical policy, told me.

More than fifty companies around the world have already contacted the Patent Pool to obtain a sublicense to produce the drug, and the Gates Foundation has pledged a hundred and twenty million dollars to support generic-drug makers. Charles Gore, the Patent Pool’s executive director, recently said that, “for large parts of the world that have not got good vaccine coverage, this is really a godsend.” Of course, the same challenges of testing and distribution will apply everywhere.

Last spring, as a doctor caring for COVID patients, I was often dismayed by how little we had to offer. We tried hydroxychloroquine, blood thinners, and various oxygen-delivery devices and ventilator maneuvers; mostly, we watched as patients got better or got worse on their own. In the evenings, as I walked the city’s deserted streets, I often asked myself what kinds of treatment I wished we had. The best thing, I thought, would be a pill that people could take at home, shortly after infection, to halt the cascade of biological processes that sends them to the hospital, the I.C.U., or worse.

We will soon have not one but two such treatments. Outside of the vaccines, the new antiviral drugs are the most important pharmacologic advance of the pandemic. As the coronavirus becomes endemic, we’ll need additional tools to treat the inevitable infections that will continue to strike both vaccinated and unvaccinated people. These drugs will do that, reducing the damage that the coronavirus can inflict and, possibly, cordoning off avenues through which it can spread. Still, insuring that they are meaningfully and equitably used will require strength in the areas in which the U.S. has struggled: early and accessible testing; communication and coördination across health-care providers; fighting misinformation and building trust in rapid scientific advances. Just as vaccines don’t help without shots in arms, antivirals can’t work without pills in people.

Source: https://www.newyorker.com/

More on the Coronavirus

• COVID is likely to become an endemic disease. How will our immune systems resist it?
• The case for masking up again indoors in New York City.
• Suddenly, (some) Republicans are all in on the vaccine.
• The outlook for life in a half-vaccinated country.
• A dreamy, disorienting reopening in New York.
• What does the Delta variant mean for the economy?
• Sign up for our daily newsletter to receive the best stories from The New Yorker.
  • “First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA” (Press release). Medicines and Healthcare products Regulatory Agency (MHRA). 4 November 2021.
  •  
  • “Summary of Product Characteristics for Lagevrio”. Medicines and Healthcare products Regulatory Agency (MHRA). 4 November 2021. Retrieved 4 November 2021.
  •  
  • “Regulatory approval of Lagevrio (molnupiravir)”. Medicines and Healthcare products Regulatory Agency (MHRA). 4 November 2021. Retrieved 4 November 2021.
  •  
  • “Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia”. Science Translational Medicine. 11 (515): eaax5866. doi:10.1126/scitranslmed.aax5866. PMC 6848974. PMID 31645453.
  •  
  • Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model”. Translational Research. 218: 16–28. doi:10.1016/j.trsl.2019.12.002. PMC 7568909. PMID 31945316.
  •  
  • Daily pill to treat COVID could be just months away”. ABC News. Kaiser Health News. Archived from the original on 29 September 2021. Retrieved 29 September 2021.
  •  
  • “Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World”. Merck (Press release). 4 November 2021. Retrieved 4 November 2021.
  •  
  • Molnupiravir Mutations”. Science (blog).
  •  
  • Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2″. Antimicrobial Agents and Chemotherapy. 65 (5). doi:10.1128/AAC.02428-20. PMC 8092915. PMID 33649113.
  •  
  • The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva”. Journal of Pharmaceutical and Biomedical Analysis. 206: 114356. doi:10.1016/j.jpba.2021.114356. PMC 7611757. PMID 34509661. S2CID 237493842.
  •  
  • Mole B (October 2021). “Meet molnupiravir, Merck’s Thor-inspired pill that hammers COVID”. Ars Technica. Retrieved 2 October 2021.
  •  
  • An emerging antiviral takes aim at COVID-19″. C&EN. Retrieved 2 October 2021.
  • Molnupiravir: coding for catastrophe”. Nature Structural & Molecular Biology. 28 (9): 706–708. doi:10.1038/s41594-021-00657-8. PMID 34518697. S2CID 237507937.
  •  
  • Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19″. Molecules. 26 (19): 3–16. doi:10.3390/molecules26195795. PMC 8510125. PMID 3464133.
  •  
  • Oral Drug Tested at Georgia State Recommended for Emergency Use Authorization to Treat COVID-19 Oral Drug Tested at Georgia State Recommended for Emergency Use Authorization to Treat COVID-19″. Institute for Biomedical Sciences Georgia State University. Retrieved 3 October 2021.
  • Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets”. Nature Microbiology. 6 (1): 11–18. doi:10.1038/s41564-020-00835-2. PMC 7755744. PMID 33273742.
  •  
  • Lives Were Lost’ as Warnings Went Unheeded, Whistle-Blower Tells House”. The New York Times.
  •  
  • Emails offer look into whistleblower charges of cronyism behind potential COVID-19 drug”. Science. doi:10.1126/science.abc7055.
  •  
  • Merck pushes ahead on COVID-19 treatment, vaccines”. Archived from the original on 14 February 2021. Retrieved 31 July
  •  
  • Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment”. Stat. Retrieved 2 October 2021.
  •  
  • “Merck’s experimental pill to treat covid-19 cuts risk of hospitalization and death in half, the pharmaceutical company reports”. The Washington Post. Retrieved 3 October 2021.
  •  
  • Weintraub K. “New antiviral is highly effective, study finds, and is stirring hope that COVID-19 could be treated by a pill”. USA Today. Retrieved 3 October 2021.
  •  
  • “Biden Administration to Invest $3 Billion from American Rescue Plan as Part of COVID-19 Antiviral Development Strategy”. U.S. Department of Health & Human Services (Press release). 17 June 2021. Archived from the original on 17 June 2021. Retrieved 17 June 2021.
  •  
  • “Biden Administration announces U.S. government procurement of Merck’s investigational antiviral medicine for COVID-19 treatment” (Press release). U.S. Department of Health & Human Services. 9 June 2021. Archived from the original on 1 October 2021. Retrieved 1 October 2021.
  •  
  • A Pill to Treat Covid-19? The U.S. Is Betting on It”. The New York Times. ISSN 0362-4331. Archived from the original on 17 June 2021. Retrieved 17 June 2021.
  •  
  • “The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries”. Merck (Press release). Retrieved 28 October 2021.
  •  
  • Merck says a trial shows it has produced the first effective antiviral pill for Covid”. The New York Times. Archived from the original on 1 October 2021. Retrieved 1 October 2021.
  •  
  • “Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults”. Merck (Press release). Retrieved 17 October 2021.
  •  
  • “FDA to Hold Advisory Committee Meeting to Discuss Merck and Ridgeback’s EUA Application for COVID-19 Oral Treatment”. U.S. Food and Drug Administration (FDA) (Press release). 18 October 2021. Retrieved 19 October 2021.
  •  
  • “TGA grants provisional determination to Merck Sharp & Dohme’s antiviral COVID-19 treatment Molnupiravir”. Therapeutic Goods Administration (TGA). 9 August 2021. Retrieved 6 November 2021.
  •  
  • “Japan in talks to procure Merck oral drug for mild COVID-19 symptoms”. The Japan Times. 4 October 2021. Retrieved 6 November 2021.
  •  
  • Alexa Phillips, COVID-19: UK shows interest in antiviral pill molnupiravir after trial shows it could halve hospitalisations and deaths, Sky News (2 October 2021).
  •  
  • “No 10 to buy new antiviral treatments for Covid in time for winter”. The Guardian. 20 October 2021.
  •  
  • Korea is negotiating to advance purchase oral antiviral COVID-19 drug, The Dong-a Ilbo (4 October 2021).
  •  
  • “Malaysia in talks to procure Merck’s Covid-19 pills”. The Straits Times. 2 October 2021. Archived from the original on 2 October 2021. Retrieved 3 October 2021.
  •  
  • “COVID-19: EMA starts rolling review of molnupiravir”. European Medicines Agency. 25 October 2021. Retrieved 6 November 2021.
  •  
  • Reed J (4 November 2021). “First pill to treat Covid gets approval in UK”. BBC News Online. Retrieved 4 November 2021.
  • UK first to approve ‘game-changing’ antiviral Covid pill”. The Times. Retrieved 5 November 2021.
  • Why the federal government has bought 300,000 doses of a COVID-treating pill that hasn’t been approved yet”. ABC News (Australia). Retrieved 4 October 2021.
  •  
  • Covid-19: Pharmac signs deal for experimental treatment pill molnupiravir”. Stuff. Archived from the original on 11 October 2021. Retrieved 11 October 2021.
  •  
  • “Eskayef, Beximco get DGDA’s marketing authorisation for Covid-19 pill molnupiravir”. The Daily Star. 9 November 2021. Retrieved 10 November 2021.
  •  
  • “Oral medicine for Covid-19 now available in Bangladesh”. The Business Standard. 9 November 2021. Retrieved 10 November 2021.
  •  
  • “Eskayef’s Covid pill hits market”. The Daily Star. 10 November 2021. Retrieved 10 November 2021.
  •  
  • “Bangladesh’s Beximco to sell first generic version of Merck COVID-19 pill”. Reuters. 9 November 2021. Retrieved 10 November 2021.
  •  
• “Bangladesh’s Beximco to sell generic version of Merck Covid-19 pill”. The Times of India. 9 November 2021. Retrieved 10 November 2021.